Pricing Log in Create free account
Saturday 17 October 2026 Export IMRN’s income statement to Excel — free account

IMMURON

IMRN Healthcare Biotechnology

IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.

0.98 0.05 −4.85%
Market cap
$8.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
n/a
Beneish M
89.24
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 44.51%

Capital & Financial Ratios $m

Market Cap 8.31
Revenue 1.74
Net Income (3.38)
Free Cash Flow (10.47)
Net Debt (6.12)
Current Ratio 7.17 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 98.57% (at or above 15%: strong)
Next Y EPS Growth (26.89%) (below 0%: weak)
Next Y revenue growth —
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −3.5×, against a ten-year median of −6.1×; over the ten years it ranged from −24.7× in 2022 to −0.6× in 2020.
EV/FCF against its own 10 years 42.35%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 13 8 2 6
Receivables 0 1 1 1
Inventory 1 1 1 2
Other 0 0 2 0
14 10 6 9
2023 2024 2025 2026
Payables 1 1 1 1
ST’ Debt — — — —
Other 0 0 0 0
1 2 1 1

Compound Annual Growth %

10y 5y 3y
Sales 21.54% 116.96% 62.73%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 7.51% (17.10%) (16.90%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — 5
’25 — — — — 5
’24 — — — — 3
’23 — — — — 1
’22 — — — — 1
’21 — — — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (2)
’25 — — — — (4)
’24 — — — — (4)
’23 — — — — (2)
’22 — — — — (2)
’21 — — — — (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — (2) — (2) (2)
’25 — (4) — (3) (4)
’24 — (4) — (1) (4)
’23 — (2) — (1) (2)
’22 — (2) — (2) (2)
’21 — (3) — (2) (3)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (0.37)
’25 — — — — (0.59)
’24 — — — — (0.80)
’23 — — — — (0.45)
’22 — — — — (0.36)
’21 — — — — (1.17)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 4.47 5.15 2.23 1.55 2.32 1.39 1.48 1.59 0.68 0.68

Analyst estimates 2027–2029

Powerpack
High 16.34 16.70 8.46 28.99 9.23 4.40 3.21 5.96 2.48 1.99
People
People Employees 7 5 6 5 4 5 6 7 7 7
Revenue/emp, $m 0.15 0.29 0.28 0.34 0.03 0.11 0.20 0.46 0.67 0.75
Income, $m
Income, $m Revenue 1 1 2 2 0 1 1 3 5 5
Gross margin, % 75.82 77.28 72.05 72.65 65.01 68.42 72.54 68.06 65.39 64.50
EBT (5) (2) (3) (2) (6) (2) (3) (5) (3) (2)
EBT margin, % (487.34) (163.38) (194.04) (116.23) (5,752.89) (373.05) (209.82) (141.49) (71.58) (47.71)
Net income (5) 0 (3) (2) (6) (2) (3) (5) (3) (2)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.40 0.43 0.47 0.38 0.02 0.10 0.21 0.56 0.82 0.70
Earnings (1.58) (0.71) (0.92) (0.45) (1.17) (0.36) (0.45) (0.80) (0.59) (0.37)
Cash flow (2.00) (0.82) (0.36) (0.48) (0.55) (0.40) (0.31) (0.68) (0.69) (0.30)
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (2.00) (0.82) (0.36) (0.48) (0.55) (0.40) (0.31) (0.68) (0.69) (0.30)
Book value 1.87 1.96 1.45 0.86 3.50 2.96 2.32 1.46 0.91 1.02
Shares, m 3 3 4 4 6 6 6 6 6 7
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales 0.00 0.00 0.00 (0.63) (10.00) (24.73) (7.30) (4.35) (1.01) (3.47)
EV/FCF 0.00 0.00 0.54 0.45 2.27 1.77 1.99 1.00 0.15 0.58
Cash, $m
Cash, $m Operating cash flow (5) (3) (1) (2) (3) (2) (2) (4) (4) (2)
Capex 0 0 0 0 0 0 0 0 — 0
Free cash flow (5) (3) (1) (2) (3) (2) (2) (4) (4) (2)
Balance, $m
Balance, $m Working capital 5 5 4 3 18 16 12 8 5 8
Total debt 0 — — 0 0 0 0 — — —
Net debt (3) (4) (4) (2) (19) (16) (13) (8) (2) (6)
Shareholders’ equity 5 7 5 4 19 17 13 8 5 8
Returns, %
Returns, % ROA (164.22) (34.81) (49.86) (38.21) (51.40) (10.83) (15.53) (36.39) (40.31) (32.26)
ROIC (153.23) (47.94) (129.77) (76.44) (618.08) (168.08) (357.94) (547.06) (80.60) (146.14)
ROE (118.87) (40.60) (56.16) (43.45) (54.15) (11.45) (16.98) (42.24) (49.82) (39.02)
Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · fundamentals updated 6 Oct 2026

Charts ten years each

IMMURON vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NKGN NKGen Biotech, Inc. $8.8M — (loss-making) — — n/m +28.68% (above 0%: growing) 100.00% 0.00% Compare
CSCIF COSCIENS Biopharma Inc. $8.6M 1.0× — +30.04% (above 0%: growing) n/m +113.30% (above 0%: growing) 55.27% 13.43% Compare
IMRN IMMURON $8.3M — (loss-making) — +757.00% (above 0%: growing) +12.00% (above 0%: growing) +42.55% (above 0%: growing) 72.16% 0.00%
ADIL Adial Pharmaceuticals, Inc. $8.3M — (loss-making) — — n/m −263.66% (below 0%: shrinking) 0.00% 0.00% Compare
BOLT Bolt Biotherapeutics, Inc. $8.2M — (loss-making) — (loss-making) −99.72% (below 0%: shrinking) n/m +38.87% (above 0%: growing) 100.00% (167,480.00%) Compare
SNTI Senti Biosciences, Inc. $8.1M — (loss-making) — (loss-making) −98.68% (below 0%: shrinking) n/m −7.48% (below 0%: shrinking) 100.00% (85,229.41%) Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR $8.1M — (loss-making) — — n/m −510.28% (below 0%: shrinking) 0.00% 0.00% Compare
XTLB XTL Biopharmaceuticals Ltd. $8.1M — (loss-making) — −39.32% (below 0%: shrinking) n/m +46.78% (above 0%: growing) 0.00% 0.00% Compare
KPTI Karyopharm Therapeutics Inc. $8.0M — (loss-making) — (loss-making) −11.86% (below 0%: shrinking) n/m −33.34% (below 0%: shrinking) 96.75% (67.38%) Compare
Median of peers $8.2M — — −39.32% — +10.60% 76.01% 0.00%

All 614 Biotechnology stocks →

IMMURON (IMRN) key facts

  • Strength: IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025.
  • IMMURON (IMRN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, IMRN traded at $0.98, a market capitalization of $8.3 million.
  • Return on equity was −39.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 6, 2026.

IMMURON (IMRN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IMRN · Data as of Oct 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com